Commercially known as Doptelet, Avatrombopag is now available for adult ITP patients who have failed to achieve a platelet count increase after first-line treatment.

Avatrombopag is an oral medication that does not have any specified dietary restrictions and is advised to be taken with food. Avatrombopag does not require liver safety monitoring for patients without a pre-existing liver condition.

Common side effects are usually mild but may include:

• fever;
• easy bruising or bleeding (nosebleeds, bleeding gums), purple or red spots on your skin;
• feeling tired;
• headache, joint pain;
• cold symptoms such as runny or stuffy nose, sneezing, sore throat;
• nausea, stomach pain; or
• swelling in your hands or feet.

If you experience any of the following symptoms, we encourage you to contact your medical professional immediately or call 000:

• Signs of a blood clot
  • chest pains, shortness of breath;
  • fast heartbeats
  • pain, swelling, and redness in one or both legs;
  • stomach pain or tenderness;
  • sudden fever or chills, yellowing of the skin or eyes; or
  • bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
• Allergy or hypersensitivity:
  • shortness or breath;
  • wheezing or difficulty breathing;
  • swelling of the face, lips, tongue or other areas of the body; or
  • itching or hives

# These side effects were reported by patients in the initial trials. After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.